■在这项试点研究中，我们已经评估了AFO-202菌株和N-163菌株在健康人类受试者中产生的黑色酵母出芽的β1,3-1,6葡聚糖的特定代谢和免疫相关益处。
■16名健康的日本男性志愿者（年龄40至60岁）参加了这项临床试验。他们分为四组（每组n=4）：第一组消耗AFO-202β-葡聚糖（每天2袋1克），IA为35天，IB为21天；第二组消耗了AFO-202β-葡聚糖（2小袋，每袋1克）和N-163β-葡聚糖（每天1袋15克凝胶）的组合，IIA为35天,IIB为21天。
■HbA1C和糖化白蛋白（GA）降低，嗜酸性粒细胞和单核细胞显著增加，D-二聚体水平边际降低，中性粒细胞与淋巴细胞比率（NLR）降低，在治疗前后的I组中观察到淋巴细胞与CRP比值(LCR)和白细胞与CRP比值(LeCR)的升高.降低总胆固醇和LDL胆固醇，CD11b的减少，血清铁蛋白,半乳糖凝集素-3和纤维蛋白原在II组治疗前和治疗后的差异很大。然而,两组第21天和第35天之间无统计学差异.
■这一结果值得进行更大规模的临床试验，以探索这些安全食品补充剂在预防和预防因代谢失调引起的疾病方面的潜力。比如脂肪肝,和COVID-19等感染，其中平衡的免疫调节至关重要，除了作为传染病和非传染病现有治疗方法的辅助手段。
UNASSIGNED: In this pilot
study, we have evaluated the specific metabolic and immune-related benefits of the AFO-202 strain and N-163 strain of black yeast Aureobasidium pullulans-produced beta 1,3-1,6 glucan in healthy human subjects.
UNASSIGNED: Sixteen healthy Japanese male volunteers (aged 40 to 60 years) took part in this clinical
trial. They were divided into four groups (n = 4 each): Group I consumed AFO-202 beta-glucan (2 sachets of 1 g each per day), IA for 35 days and IB for 21 days; Group II consumed a combination of AFO-202 beta-glucan (2 sachets of 1 g each) and N-163 beta-glucan (1 sachet of 15 g gel each per day), IIA for 35 days and IIB for 21 days.
UNASSIGNED: Decrease in HbA1C and glycated albumin (GA), significant increase of eosinophils and monocytes and marginal decrease in D-dimer levels, decrease in neutrophil-to-lymphocyte ratio (NLR), with an increase in the lymphocyte-to-CRP ratio (LCR) and leukocyte-to-CRP ratio (LeCR) was observed in Group I between pre- and post-treatment. Decrease in total and LDL cholesterol, a decrease of CD11b, serum ferritin, galectin-3 and fibrinogen were profound in Group II between pre- and post-treatment. However, there was no statistically significant difference between day 21 and day 35 among the groups.
UNASSIGNED: This outcome warrants larger clinical trials to explore the potentials of these safe food supplements in the prevention and prophylaxis of diseases due to dysregulated metabolism, such as fatty liver disease, and infections such as COVID-19 in which balanced immunomodulation are of utmost importance, besides their administration as an adjunct to existing therapeutic approaches of both communicable and non-communicable diseases.
PDF(Pubmed)